Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Phase 2

Completed

Conditions: Untreated T-cell Angioimmunoblastic Lymphoma

Interventions: Drug: Rituximab
Drug: Prednisone
Drug: Doxorubicine
Drug: Cyclophosphamide
Drug: Vincristine

First Posted Date: 2005-09-15

Last Posted Date: 2017-03-13

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 27

Registration Number: NCT00169156

Locations: 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷
Centre Henri Becquerel, Rouen, France

and more 1 locations

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

Not Applicable

Withdrawn

Conditions: End Stage Renal Disease

First Posted Date: 2005-09-14

Last Posted Date: 2015-10-14

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00167791

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Phase 2

Withdrawn

Conditions: Idiopathic Thrombocytopenic Purpura (ITP)

First Posted Date: 2005-09-12

Last Posted Date: 2018-07-17

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT00161564

Locations: 🇺🇸
Weill Medical College of Cornell University Division of Pediatric Hematology-Oncology, New York, New York, United States

Rituximab in the Treatment of Graves' Disease

Phase 1

Completed

Conditions: Graves´ Disease
Thyroid Associated Ophthalmopathy

First Posted Date: 2005-09-08

Last Posted Date: 2006-10-06

Lead Sponsor: Odense University Hospital

Target Recruit Count: 20

Registration Number: NCT00150111

Locations: 🇩🇰
Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark
🇩🇰
Department of Hematology, Odense University Hospital, Odense, Denmark